BTIG Maintains Buy on LifeMD, Lowers Price Target to $9

Benzinga Newsdesk www.benzinga.com Negative 51.1%

Neg 51.1% Neu 0% Pos 0%

BTIG analyst David Larsen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $9.

Comments

No comments yet. Be the first!